1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Research In Brief

Updates on St. Jude ICD leads, TAVR registry data and breast cancer brachytherapy compared to conventional irradiation.

The rate of confirmed cases of the “externalized conductor” phenomenon with St. Jude Medical’s no-longer-marketed, silicone-insulated Riata implantable defibrillator lead climbed to 0.3% as of Feb. 29, according to the firm’s latest cardiac rhythm management product performance report, released May 1.

The rate was 0.17% as of Dec. 31 and 0.1% of last November, when St. Jude issued an advisory for the products that was categorized as a class I recall...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

More from R&D